Dr. Silverman is always on the lookout for innovations that can make recovery smoother and safer for our patients. That’s why we’re thrilled to share some exciting news: the FDA has recently approved suzetrigine (Journavx), a first-in-its-class drug that aims to transform how we manage post-operative pain—especially for those healing from foot and ankle surgeries. Let’s dive into what this means for you.
What Makes Suzetrigine Different?
Unlike traditional opioids like hydrocodone or oxycodone, suzetrigine isn’t addictive. It works by targeting the NaV1.8 sodium channel in your peripheral nervous system—the pain pathways outside your brain and spinal cord. By blocking pain signals before they even get started, it delivers relief without many of the risky side effects of opioids. No drowsiness that keeps you off your feet longer than necessary, and—most importantly—no risk of dependency. For our patients recovering from procedures like bunion surgery or ankle reconstruction, this medication could be a game-changer.
Clinical Trials For Suzetrigine
Clinical trials put suzetrigine to the test, including on patients recovering from abdominoplasty and bunionectomy surgeries. And while Dr. Silverman cannot speak to the abdominoplasty, he frequently corrects moderate to severe bunions with a minimally invasive procedure. The results of the clinical trails found that suzetrigine matched the pain relief of hydrocodone-acetaminophen, a common opioid combintion, but without the extra baggage. Over 80% of participants rated it “good” to “excellent” in terms of its effectiveness. Side effects like dizziness, headache, or nausea were reported, but they’re mild compared to the more severe potential side effects associated with opioids.
Suzetrigine isn’t just a new drug—it’s a shift in how we think about pain relief. After years of wrestling with the opioid crisis, having a nonaddictive option that works this well feels like a win for everyone. We’re optimistic it could reduce unnecessary suffering and help our patients heal smarter, not harder.
Why This Matters for Foot and Ankle Patients
Post-op pain management is a big deal at our practice. Whether you’ve had a fracture repair or a ligament reconstruction, controlling pain without slowing your healing process is key. Opioids have long been the go-to, but we’ve seen the toll they can take—sluggishness, dependency, and sometimes even delayed rehab because patients can’t get moving. Suzetrigine appears to offer a safer path forward. Imagine recovering from your surgery with clear-headed comfort, ready to start physical therapy on time and get back to your life. That’s the future we’re excited about.
So What’s The Catch?
There’s one hurdle to watch: suzetrigine’s wholesale price is set at $930 for a 60-tablet bottle, which amounts to around $15.50 per pill. For a two-week course, that will add up. We’re hopeful insurance will step in to make it accessible, or drug manufacturers will offer support programs, but we’re not expecting this to happen overnight. Dr. Silverman will continue to advocate for our patients, and he’ll keep you posted on how things shake out.
For more information, reach out to Dr. Silverman by filling out this contact form.